Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
03 Apr 2024
Historique:
received: 18 06 2023
accepted: 11 03 2024
medline: 4 4 2024
pubmed: 4 4 2024
entrez: 3 4 2024
Statut: epublish

Résumé

Despite regulating overlapping gene enhancers and pathways, CREBBP and KMT2D mutations recurrently co-occur in germinal center (GC) B cell-derived lymphomas, suggesting potential oncogenic cooperation. Herein, we report that combined haploinsufficiency of Crebbp and Kmt2d induces a more severe mouse lymphoma phenotype (vs either allele alone) and unexpectedly confers an immune evasive microenvironment manifesting as CD8

Identifiants

pubmed: 38570506
doi: 10.1038/s41467-024-47012-1
pii: 10.1038/s41467-024-47012-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2879

Subventions

Organisme : Leukemia and Lymphoma Society (Leukemia & Lymphoma Society)
ID : SCOR 7021-20

Informations de copyright

© 2024. The Author(s).

Références

Baylin, S. B. & Jones P. A. Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol. 8 (2016).
Dawson, M. A. & Kouzarides, T. Cancer epigenetics: from mechanism to therapy. Cell 150, 12–27 (2012).
pubmed: 22770212 doi: 10.1016/j.cell.2012.06.013
Duy, C., Beguelin, W. & Melnick, A. Epigenetic mechanisms in leukemias and lymphomas. Cold Spring Harb. Perspect. Med. 10 (2020).
Okosun, J. et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat. Genet. 46, 176–181 (2014).
pubmed: 24362818 doi: 10.1038/ng.2856
Pasqualucci, L. et al. Genetics of follicular lymphoma transformation. Cell Rep. 6, 130–140 (2014).
pubmed: 24388756 pmcid: 4100800 doi: 10.1016/j.celrep.2013.12.027
Chapuy, B. et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 24, 679–690 (2018).
pubmed: 29713087 pmcid: 6613387 doi: 10.1038/s41591-018-0016-8
Mlynarczyk, C., Fontan, L. & Melnick, A. Germinal center-derived lymphomas: the darkest side of humoral immunity. Immunol. Rev. 288, 214–239 (2019).
pubmed: 30874354 pmcid: 6518944 doi: 10.1111/imr.12755
Green, M. R. et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 121, 1604–1611 (2013).
pubmed: 23297126 pmcid: 3587323 doi: 10.1182/blood-2012-09-457283
Green, M. R. et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc. Natl Acad. Sci. USA 112, E1116–E1125 (2015).
pubmed: 25713363 pmcid: 4364211 doi: 10.1073/pnas.1501199112
Calo, E. & Wysocka, J. Modification of enhancer chromatin: what, how, and why? Mol. Cell 49, 825–837 (2013).
pubmed: 23473601 doi: 10.1016/j.molcel.2013.01.038
Froimchuk, E., Jang, Y. & Ge, K. Histone H3 lysine 4 methyltransferase KMT2D. Gene 627, 337–342 (2017).
pubmed: 28669924 pmcid: 5546304 doi: 10.1016/j.gene.2017.06.056
Tie, F. et al. CBP-mediated acetylation of histone H3 lysine 27 antagonizes Drosophila Polycomb silencing. Development 136, 3131–3141 (2009).
pubmed: 19700617 pmcid: 2730368 doi: 10.1242/dev.037127
Creyghton, M. P. et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl Acad. Sci. USA 107, 21931–21936 (2010).
pubmed: 21106759 pmcid: 3003124 doi: 10.1073/pnas.1016071107
Raisner, R. et al. Enhancer activity requires CBP/P300 bromodomain-dependent histone H3K27 acetylation. Cell Rep. 24, 1722–1729 (2018).
pubmed: 30110629 doi: 10.1016/j.celrep.2018.07.041
Garcia-Ramirez, I. et al. Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice. Blood 129, 2645–2656 (2017).
pubmed: 28288979 pmcid: 5428458 doi: 10.1182/blood-2016-08-733469
Hashwah, H. et al. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth. Proc. Natl Acad. Sci. USA 114, 9701–9706 (2017).
pubmed: 28831000 pmcid: 5594639 doi: 10.1073/pnas.1619555114
Jiang, Y. et al. CREBBP inactivation promotes the development of HDAC3-dependent lymphomas. Cancer Discov. 7, 38–53 (2017).
pubmed: 27733359 doi: 10.1158/2159-8290.CD-16-0975
Ortega-Molina, A. et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat. Med. 21, 1199–1208 (2015).
pubmed: 26366710 pmcid: 4676270 doi: 10.1038/nm.3943
Zhang, J. et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat. Med. 21, 1190–1198 (2015).
pubmed: 26366712 pmcid: 5145002 doi: 10.1038/nm.3940
Zhang, J. et al. The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma. Cancer Discov. 7, 322–337 (2017).
pubmed: 28069569 pmcid: 5386396 doi: 10.1158/2159-8290.CD-16-1417
Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553–567 (2010).
pubmed: 21130701 pmcid: 4105845 doi: 10.1016/j.ccr.2010.11.015
Ma MCJ et al. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica 107, 690–701 (2022).
pubmed: 33792219
Schmitz, R. et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N. Engl. J. Med. 378, 1396–1407 (2018).
pubmed: 29641966 pmcid: 6010183 doi: 10.1056/NEJMoa1801445
Lacy, S. E. et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood 135, 1759–1771 (2020).
pubmed: 32187361 pmcid: 7259825 doi: 10.1182/blood.2019003535
Wright, G. W. et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 37, 551–568.e514 (2020).
pubmed: 32289277 pmcid: 8459709 doi: 10.1016/j.ccell.2020.03.015
Han, G. et al. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discov. 3, 428–443 (2022).
pubmed: 35687817 pmcid: 9894575 doi: 10.1158/2643-3230.BCD-21-0075
Casola, S. et al. Tracking germinal center B cells expressing germ-line immunoglobulin gamma1 transcripts by conditional gene targeting. Proc. Natl Acad. Sci. USA 103, 7396–7401 (2006).
pubmed: 16651521 pmcid: 1464351 doi: 10.1073/pnas.0602353103
Kang-Decker, N. et al. Loss of CBP causes T cell lymphomagenesis in synergy with p27Kip1 insufficiency. Cancer Cell 5, 177–189 (2004).
pubmed: 14998493 doi: 10.1016/S1535-6108(04)00022-4
Lee, J. E. et al. H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation. Elife 2, e01503 (2013).
pubmed: 24368734 pmcid: 3869375 doi: 10.7554/eLife.01503
Egle, A., Harris, A. W., Bath, M. L., O’Reilly, L. & Cory, S. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood 103, 2276–2283 (2004).
pubmed: 14630790 doi: 10.1182/blood-2003-07-2469
Ogilvy, S. et al. Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc. Natl Acad. Sci. USA 96, 14943–14948 (1999).
pubmed: 10611317 pmcid: 24752 doi: 10.1073/pnas.96.26.14943
Florek, M. et al. Freeze and thaw of CD4+CD25+Foxp3+ regulatory T cells results in loss of CD62L expression and a reduced capacity to protect against graft-versus-host disease. PLoS One 10, e0145763 (2015).
pubmed: 26693907 pmcid: 4691201 doi: 10.1371/journal.pone.0145763
Jacobsen, J. T. et al. Expression of Foxp3 by T follicular helper cells in end-stage germinal centers. Science 373 (2021).
Linterman, M. A. et al. Foxp3+ follicular regulatory T cells control the germinal center response. Nat. Med. 17, 975–982 (2011).
pubmed: 21785433 pmcid: 3182542 doi: 10.1038/nm.2425
Kridel, R. et al. Histological transformation and progression in follicular lymphoma: a clonal evolution study. PLoS Med. 13, e1002197 (2016).
pubmed: 27959929 pmcid: 5154502 doi: 10.1371/journal.pmed.1002197
Cannon, R. L., Dave, J. V. & Bezdek, J. C. Efficient implementation of the Fuzzy c-means clustering algorithms. IEEE Trans. Pattern Anal. Mach. Intell. 8, 248–255 (1986).
pubmed: 21869343 doi: 10.1109/TPAMI.1986.4767778
Rivas, M. A. et al. Cohesin core complex gene dosage contributes to germinal center derived lymphoma phenotypes and outcomes. Front Immunol. 12, 688493 (2021).
pubmed: 34621263 pmcid: 8490713 doi: 10.3389/fimmu.2021.688493
Street, K. et al. Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. BMC Genom. 19, 477 (2018).
doi: 10.1186/s12864-018-4772-0
Rivas, M. A. et al. Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation. Nat. Immunol. 22, 240–253 (2021).
pubmed: 33432228 pmcid: 7855695 doi: 10.1038/s41590-020-00827-8
Laidlaw, B. J. & Cyster, J. G. Transcriptional regulation of memory B cell differentiation. Nat. Rev. Immunol. 21, 209–220 (2021).
pubmed: 33024284 doi: 10.1038/s41577-020-00446-2
Song, S. & Matthias, P. D. The transcriptional regulation of germinal center formation. Front. Immunol. 9, 2026 (2018).
pubmed: 30233601 pmcid: 6134015 doi: 10.3389/fimmu.2018.02026
Chu, C. S. et al. Unique immune cell coactivators specify locus control region function and cell stage. Mol. Cell 80, 845–861 e810 (2020).
pubmed: 33232656 pmcid: 7737631 doi: 10.1016/j.molcel.2020.10.036
Chen, J., Bardes, E. E., Aronow, B. J. & Jegga, A. G. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 37, W305–W311 (2009).
pubmed: 19465376 pmcid: 2703978 doi: 10.1093/nar/gkp427
Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90–W97 (2016).
pubmed: 27141961 pmcid: 4987924 doi: 10.1093/nar/gkw377
Hoekstra, M. E., Vijver, S. V. & Schumacher, T. N. Modulation of the tumor micro-environment by CD8(+) T cell-derived cytokines. Curr. Opin. Immunol. 69, 65–71 (2021).
pubmed: 33862306 pmcid: 7610766 doi: 10.1016/j.coi.2021.03.016
Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934–947 (2013).
pubmed: 24119843 doi: 10.1016/j.cell.2013.09.053
Bunting, K. L. et al. Multi-tiered reorganization of the genome during B cell affinity maturation anchored by a germinal center-specific locus control region. Immunity 45, 497–512 (2016).
pubmed: 27637145 pmcid: 5033726 doi: 10.1016/j.immuni.2016.08.012
Doane, A. S. et al. OCT2 pre-positioning facilitates cell fate transition and chromatin architecture changes in humoral immunity. Nat. Immunol. 22, 1327–1340 (2021).
pubmed: 34556886 pmcid: 9829245 doi: 10.1038/s41590-021-01025-w
Hatzi, K. et al. A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. Cell Rep. 4, 578–588 (2013).
pubmed: 23911289 doi: 10.1016/j.celrep.2013.06.016
Huang, C., Hatzi, K. & Melnick, A. Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms. Nat. Immunol. 14, 380–388 (2013).
pubmed: 23455674 pmcid: 3604075 doi: 10.1038/ni.2543
Ranuncolo, S. M. et al. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat. Immunol. 8, 705–714 (2007).
pubmed: 17558410 doi: 10.1038/ni1478
Polo, J. M., Ci, W., Licht, J. D. & Melnick, A. Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells. Blood 112, 644–651 (2008).
pubmed: 18487509 pmcid: 2481532 doi: 10.1182/blood-2008-01-131813
Wang, S. P. et al. A UTX-MLL4-p300 transcriptional regulatory network coordinately shapes active enhancer landscapes for eliciting transcription. Mol. Cell 67, 308–321.e306 (2017).
pubmed: 28732206 pmcid: 5574165 doi: 10.1016/j.molcel.2017.06.028
Pradeepa, M. M. Causal role of histone acetylations in enhancer function. Transcription 8, 40–47 (2017).
pubmed: 27792455 doi: 10.1080/21541264.2016.1253529
Fasciani, A. et al. MLL4-associated condensates counterbalance Polycomb-mediated nuclear mechanical stress in Kabuki syndrome. Nat. Genet. 52, 1397–1411 (2020).
pubmed: 33169020 pmcid: 7610431 doi: 10.1038/s41588-020-00724-8
Sabari, B. R. et al. Coactivator condensation at super-enhancers links phase separation and gene control. Science 361, eaar3958 (2018).
pubmed: 29930091 pmcid: 6092193 doi: 10.1126/science.aar3958
Vlasevska, S. et al. KMT2D acetylation by CREBBP reveals a cooperative functional interaction at enhancers in normal and malignant germinal center B cells. Proc. Natl Acad. Sci. USA 120, e2218330120 (2023).
pubmed: 36893259 pmcid: 10089214 doi: 10.1073/pnas.2218330120
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A. & Bluestone, J. A. CD28 costimulation: from mechanism to therapy. Immunity 44, 973–988 (2016).
pubmed: 27192564 pmcid: 4932896 doi: 10.1016/j.immuni.2016.04.020
Cannons, J. L. et al. Optimal germinal center responses require a multistage T cell:B cell adhesion process involving integrins, SLAM-associated protein, and CD84. Immunity 32, 253–265 (2010).
pubmed: 20153220 pmcid: 2830297 doi: 10.1016/j.immuni.2010.01.010
Liu, D. et al. T-B-cell entanglement and ICOSL-driven feed-forward regulation of germinal centre reaction. Nature 517, 214–218 (2015).
pubmed: 25317561 doi: 10.1038/nature13803
Reimer, D. et al. Early CCR6 expression on B cells modulates germinal centre kinetics and efficient antibody responses. Immunol. Cell Biol. 95, 33–41 (2017).
pubmed: 27465674 doi: 10.1038/icb.2016.68
Tan, T. C. J. et al. Suboptimal T-cell receptor signaling compromises protein translation, ribosome biogenesis, and proliferation of mouse CD8 T cells. Proc. Natl Acad. Sci. USA 114, E6117–E6126 (2017).
pubmed: 28696283 pmcid: 5544288 doi: 10.1073/pnas.1700939114
Mondello, P. et al. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discov. 10, 440–459 (2020).
pubmed: 31915197 pmcid: 7275250 doi: 10.1158/2159-8290.CD-19-0116
Heward, J. et al. KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. Blood 138, 370–381 (2021).
pubmed: 33786580 pmcid: 8351530 doi: 10.1182/blood.2020008743
Blaker, Y. N. et al. The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era. Br. J. Haematol. 175, 102–114 (2016).
pubmed: 27341313 doi: 10.1111/bjh.14201
Chow, S. et al. Myeloma immunoglobulin rearrangement and translocation detection through targeted capture sequencing. Life Sci. Alliance 6, e202201543 (2023).
pubmed: 36328595 doi: 10.26508/lsa.202201543
Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380–381 (2015).
pubmed: 25924071 doi: 10.1038/nmeth.3364
Hsieh, T. C., Ma, K. H., Chao, A. & McInerny, G. iNEXT: an R package for rarefaction and extrapolation of species diversity (Hill numbers). Methods Ecol. Evol. 7, 1451–1456 (2016).
doi: 10.1111/2041-210X.12613
Folco, E. G., Lei, H., Hsu, J. L. & Reed, R. Small-scale nuclear extracts for functional assays of gene-expression machineries. J Vis Exp. 64, 4140 (2012).
Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573–3587.e3529 (2021).
pubmed: 34062119 pmcid: 8238499 doi: 10.1016/j.cell.2021.04.048
Goodarzi, H., Elemento, O. & Tavazoie, S. Revealing global regulatory perturbations across human cancers. Mol. Cell 36, 900–911 (2009).
pubmed: 20005852 pmcid: 2900319 doi: 10.1016/j.molcel.2009.11.016
Shaffer, A. L. et al. A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol. Rev. 210, 67–85 (2006).
pubmed: 16623765 doi: 10.1111/j.0105-2896.2006.00373.x
Elemento, O., Slonim, N. & Tavazoie, S. A universal framework for regulatory element discovery across all genomes and data types. Mol. Cell 28, 337–350 (2007).
pubmed: 17964271 pmcid: 2900317 doi: 10.1016/j.molcel.2007.09.027
Schwammle, V. & Jensen, O. N. A simple and fast method to determine the parameters for fuzzy c-means cluster analysis. Bioinformatics 26, 2841–2848 (2010).
pubmed: 20880957 doi: 10.1093/bioinformatics/btq534
Corces, M. R. et al. An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nat. Methods 14, 959–962 (2017).
pubmed: 28846090 pmcid: 5623106 doi: 10.1038/nmeth.4396
Loven, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320–334 (2013).
pubmed: 23582323 pmcid: 3760967 doi: 10.1016/j.cell.2013.03.036
Whyte, W. A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307–319 (2013).
pubmed: 23582322 pmcid: 3653129 doi: 10.1016/j.cell.2013.03.035
McLean, C. Y. et al. GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 28, 495–501 (2010).
pubmed: 20436461 pmcid: 4840234 doi: 10.1038/nbt.1630
Meers, M. P., Bryson, T. D., Henikoff, J. G. & Henikoff, S. Improved C. U. T.&RUN chromatin profiling tools. Elife 8 (2019).
van Galen, P. et al. A multiplexed system for quantitative comparisons of chromatin landscapes. Mol. Cell 61, 170–180 (2016).
pubmed: 26687680 doi: 10.1016/j.molcel.2015.11.003
Ross-Innes, C. S. et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481, 389–393 (2012).
pubmed: 22217937 pmcid: 3272464 doi: 10.1038/nature10730
Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).
pubmed: 24227677 doi: 10.1093/bioinformatics/btt656
Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010).
pubmed: 20979621 pmcid: 3218662 doi: 10.1186/gb-2010-11-10-r106
Ramirez, F. et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 44, W160–W165 (2016).
pubmed: 27079975 pmcid: 4987876 doi: 10.1093/nar/gkw257

Auteurs

Jie Li (J)

Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA.

Christopher R Chin (CR)

Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.

Hsia-Yuan Ying (HY)

Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA.

Cem Meydan (C)

Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.

Matthew R Teater (MR)

Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA.

Min Xia (M)

Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA.

Pedro Farinha (P)

BC Cancer Centre for Lymphoid Cancer, Department of Pathology and Laboratorial Medicine, University of British Columbia, Vancouver, Canada.

Katsuyoshi Takata (K)

Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, Canada.

Chi-Shuen Chu (CS)

The Laboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, NY, USA.

Yiyue Jiang (Y)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.

Jenna Eagles (J)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Verena Passerini (V)

Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Ludwig-Maximilians University (LMU) Hospital, Munich, Germany.

Zhanyun Tang (Z)

The Laboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, NY, USA.

Martin A Rivas (MA)

Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA.

Oliver Weigert (O)

Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research (ELLF), Ludwig-Maximilians University (LMU) Hospital, Munich, Germany.

Trevor J Pugh (TJ)

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Ontario Institute for Cancer Research, Toronto, ON, Canada.

Amy Chadburn (A)

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.

Christian Steidl (C)

Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, Canada.

David W Scott (DW)

BC Cancer Centre for Lymphoid Cancer, Department of Medicine, University of British Columbia, Vancouver, Canada.

Robert G Roeder (RG)

The Laboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, NY, USA.

Christopher E Mason (CE)

Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.
The WorldQuant Initiative for Quantitative Prediction, Weill Cornell Medicine, New York, NY, USA.
The Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.

Roberta Zappasodi (R)

Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA.

Wendy Béguelin (W)

Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA. web2002@med.cornell.edu.

Ari M Melnick (AM)

Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA. amm2014@med.cornell.edu.

Classifications MeSH